PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5

被引:54
作者
Patel, Abhijit A.
Chen, Ming-Hui
Renshaw, Andrew A.
D'Amico, Anthony V.
机构
[1] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Baptist Hosp Miami, Dept Pathol, Miami, FL USA
[5] Univ Connecticut, Dept Stat, Storrs, CT 06269 USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2007年 / 298卷 / 13期
关键词
D O I
10.1001/jama.298.13.1533
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context In 2005, the International Society of Urologic Pathology consensus conference recommended that men with biopsy Gleason score 3 + 4 or 4 + 3 prostate cancer and tertiary pattern 5 should have their cancer classified as Gleason score 8 or 9, respectively. Yet, the management of men with Gleason score 7 vs 8 or 9 prostate cancer differs. Objective To compare the prognostic significance of Gleason score 7 with tertiary grade 5 vs other Gleason scores with respect to time to prostate-specific antigen (PSA) failure in men with prostate cancer. Design, Setting, and Patients From 1989 to 2005, 2370 men with clinical tumor category 1c to 3b, node-negative, and nonmetastatic prostate cancer underwent definitive therapy with surgery or radiation therapy with or without hormonal therapy. A pathologist with expertise in genitourinary cancers assigned Gleason scores to the prostate needle biopsy specimens. Cox regression was used to assess whether a significant association existed between the presence of tertiary grade 5 in men with Gleason score 7 disease and time to recurrence compared with men with Gleason score 7 without tertiary grade 5, Gleason score 5 to 6, or 8 to 10 disease, adjusting for known prognostic factors and treatment. Main Outcome Measure Time to PSA failure. Results Men with Gleason score 7 and tertiary grade 5 disease had a significantly shorter time to PSA failure than men with 7 without tertiary grade 5 (median time, 5.0 vs 6.7 years, respectively; adjusted hazard ratio (HR), 0.56; 95% confidence interval [CI], 0.32-0.97; P = .04) or score of 6 or less (median time, 15.4 years; adjusted HR, 0.24; 95% CI, 0.13-0.43; P < .001). However, a significant difference was not observed when these men were compared with men with Gleason score 8 to 10 disease (median time, 5.1 years; adjusted HR, 0.96; 95% CI, 0.54-1.71; P = .90). Conclusion In this study population, men with prostate cancer having biopsy Gleason score 7 and tertiary grade 5 had a higher risk of PSA-failure when compared with men with Gleason score 7 without tertiary grade 5 and had a comparable risk with men with Gleason score 8 to 10.
引用
收藏
页码:1533 / 1538
页数:6
相关论文
共 28 条
  • [1] ALHARA M, 1994, UROLOGY, V43, P60
  • [2] Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial
    Bolla, M
    Collette, L
    Blank, L
    Warde, P
    Dubois, JB
    Mirimanoff, RO
    Storme, G
    Bernier, J
    Kuten, A
    Sternberg, C
    Mattelaer, J
    Torecilla, JL
    Pfeffer, JR
    Cutajar, CL
    Zurlo, A
    Pierart, M
    [J]. LANCET, 2002, 360 (9327) : 103 - 108
  • [3] Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer update panel report and recommendations for a standard in the reporting of surgical outcomes
    Cookson, Michael S.
    Aus, Gunnar
    Burnett, Arthur L.
    Canby-Hagino, Edith D.
    D'Amico, Anthony V.
    Dmochowski, Roger R.
    Eton, David T.
    Forman, Jeffrey D.
    Goldenberg, S. Larry
    Hernandez, Javier
    Higano, Celestia S.
    Kraus, Stephen R.
    Moul, Judd W.
    Tangen, Catherine
    Thrasher, J. Brantley
    Thompson, Ian
    [J]. JOURNAL OF UROLOGY, 2007, 177 (02) : 540 - 545
  • [4] Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
    D'Amico, AV
    Whittington, R
    Malkowicz, SB
    Schultz, D
    Blank, K
    Broderick, GA
    Tomaszewski, JE
    Renshaw, AA
    Kaplan, I
    Beard, CJ
    Wein, A
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11): : 969 - 974
  • [5] 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer - A randomized controlled trial
    D'Amico, AV
    Manola, J
    Loffredo, M
    Renshaw, AA
    DellaCroce, A
    Kantoff, PW
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (07): : 821 - 827
  • [6] Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial
    Denham, JW
    Steigler, A
    Lamb, DS
    Joseph, D
    Mameghan, H
    Turner, S
    Matthews, J
    Franklin, I
    Atkinson, C
    North, J
    Poulsen, M
    Christie, D
    Spry, NA
    Tai, KH
    Wynne, C
    Duchesne, G
    Kovacev, O
    D'Este, C
    [J]. LANCET ONCOLOGY, 2005, 6 (11) : 841 - 850
  • [7] Current practice of Gleason grading among genitourinary pathologists
    Egevad, L
    Allsbrook, WC
    Epstein, JI
    [J]. HUMAN PATHOLOGY, 2005, 36 (01) : 5 - 9
  • [8] The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma
    Epstein, JI
    Allsbrook, WC
    Amin, MB
    Egevad, LL
    Bastacky, S
    Beltrán, AL
    Berner, A
    Billis, A
    Boccon-Gibod, L
    Cheng, L
    Civantos, F
    Cohen, C
    Cohen, MB
    Datta, M
    Davis, C
    Delahunt, B
    Delprado, W
    Eble, JN
    Foster, CS
    Furusato, M
    Gaudin, PB
    Grignon, DJ
    Humphrey, PA
    Iczkowski, KA
    Jones, EC
    Lucia, S
    McCue, PA
    Nazeer, T
    Oliva, E
    Pan, CC
    Pizov, G
    Reuter, V
    Samaratunga, H
    Sebo, T
    Sesterhenn, I
    Shevchuk, M
    Srigley, JR
    Suzigan, S
    Takahashi, H
    Tamboli, P
    Tan, PH
    Têtu, B
    Tickoo, S
    Tomaszewski, JE
    Troncoso, P
    Tsuzuki, T
    True, LD
    van der Kwast, T
    Wheeler, TM
    Wojno, KJ
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2005, 29 (09) : 1228 - 1242
  • [9] HISTOLOGIC GRADING OF PROSTATE-CANCER - A PERSPECTIVE
    GLEASON, DF
    [J]. HUMAN PATHOLOGY, 1992, 23 (03) : 273 - 279
  • [10] PREDICTION OF PROGNOSIS FOR PROSTATIC ADENOCARCINOMA BY COMBINED HISTOLOGICAL GRADING AND CLINICAL STAGING
    GLEASON, DF
    MELLINGE.GT
    [J]. JOURNAL OF UROLOGY, 1974, 111 (01) : 58 - 64